Exhaled breath profiles in the monitoring of loss of control and clinical recovery in asthma

Clinical and Experimental Allergy

Volumn 47, Issue 9, 2017, Pages 1159-1169

  Brinkman, P ^a   van de Pol, M A ^a   Gerritsen, M G ^a   Bos, L D ^a   Dekker, T ^a   Smids, B S ^a   Sinha, A ^a   Majoor, C J ^a   Sneeboer, M M ^a   Knobel, H H ^b   Vink, T J ^b   de Jongh, F H ^c   Lutter, R ^a   Sterk, P J ^a   Fens, N ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Asthma; electronic nose; exacerbation; exhaled breath analysis; gas chromatography mass spectrometry; volatile organic compounds

Indexed keywords

PREDNISOLONE; VOLATILE ORGANIC COMPOUND; BIOLOGICAL MARKER; NITRIC OXIDE;

ADULT; ARTICLE; ASTHMA CONTROL QUESTIONNAIRE; BREATH ANALYSIS; CHEST TIGHTNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DYSPNEA; ELECTRONIC NOSE; EOSINOPHIL; EXPIRED AIR; FEMALE; HUMAN; LONGITUDINAL STUDY; LOSS OF ASTHMA CONTROL; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MASS FRAGMENTOGRAPHY; MODERATE PERSISTENT ASTHMA; PRICK TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT PARAMETERS; SPUTUM; WHEEZING; ASTHMA; CYTOLOGY; EXHALATION; METABOLISM; PATHOPHYSIOLOGY; SYMPTOM ASSESSMENT; YOUNG ADULT;

ADULT; ASTHMA; BIOMARKERS; BREATH TESTS; ELECTRONIC NOSE; EXHALATION; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; NITRIC OXIDE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SPUTUM; SYMPTOM ASSESSMENT; VOLATILE ORGANIC COMPOUNDS; YOUNG ADULT;

EID: 85022340011     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12965     Document Type: Article

References (59)

1. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59-99.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention 2015. Available from: http://www.ginasthma.org/. Accessed October 4, 2015
3. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218-224.
4. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl. 2002;37:1s-2s.
5. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67:199-208.
6. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483-494.
7. ten Brinke A, de Lange C, Zwinderman AH, Rabe KF, Sterk PJ, Bel EH. Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. Am J Respir Crit Care Med. 2001;164:749-753.
8. van der Schee MP, Paff T, Brinkman P, van Aalderen WM, Haarman EG, Sterk PJ. Breathomics in lung disease. Chest. 2015;147:224-231.
9. Rattray NJ, Hamrang Z, Trivedi DK, Goodacre R, Fowler SJ. Taking your breath away: metabolomics breathes life in to personalized medicine. Trends Biotechnol. 2014;32:538-548.
10. Boots AW, Bos LD, van der Schee MP, van Schooten FJ, Sterk PJ. Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises. Trends Mol Med. 2015;21:633-644.
11. Wilson AD. Advances in Electronic-Nose Technologies for the Detection of Volatile Biomarker Metabolites in the Human Breath. Metabolites. 2015;5:140-163.
12. Fens N, de Nijs SB, Peters S, Dekker T, Knobel HH, Vink TJ, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J. 2011;38:1301-1309.
13. Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, et al. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax. 2011;66:804-809.
14. Fens N, van der Sluijs KF, van de Pol MA, Dijkhuis A, Smids BS, van der Zee JS, et al. Electronic Nose Identifies Bronchoalveolar Lavage Fluid Eosinophils in Asthma. Am J Respir Crit Care Med. 2015;191:1086-1088.
15. Schleich FN, Dallinga JW, Henket M, Wouters EF, Louis R, Van Schooten FJ. Volatile organic compounds discriminate between eosinophilic and neutrophilic inflammation in vitro. J Breath Res. 2016;10:016006.
16. Sneeboer MM, Fens N, van de Pol MA, Majoor CJ, Meijers JC, Kamphuisen PW, et al. Loss of asthma control and activation of coagulation and fibrinolysis. Clin Exp Allergy. 2016;46:422-427.
17. in't Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med. 1999;160:93-99.
18. Maneechotesuwan K, Essilfie-Quaye S, Kharitonov SA, Adcock IM, Barnes PJ. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. Chest. 2007;132:98-105.
19. Belda J, Parameswaran K, Lemiere C, Kamada D, O'Byrne PM, Hargreave FE. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Respir J. 2006;13:129-133.
20. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-907.
21. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000;161:64-72.
22. Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol. 2007;120:856-862.
23. Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009;180:1076-1082.
24. Brinkman P, van der Schee M, Fens N, Pennazza G, Santonico M, D'Amico A, et al. Calibration of a (semi)-automatic measurement and control platform for centralized, simultaneous electronic nose (eNose) analyses in multi-centre trials. Eur Respir J 2012;40(Suppl 56):P4307.
25. van der Schee MP, Fens N, Brinkman P, Bos LD, Angelo MD, Nijsen TM, et al. Effect of transportation and storage using sorbent tubes of exhaled breath samples on diagnostic accuracy of electronic nose analysis. J Breath Res. 2013;7:016002.
26. Lewis NS. Comparisons between mammalian and artificial olfaction based on arrays of carbon black-polymer composite vapor detectors. Acc Chem Res. 2004;37:663-672.
27. Di Natale C, Paolesse R, D'Amico A. Metalloporphyrins based artificial olfactory receptors. Sens Actuators B Chem. 2007;121:238-246.
28. Bos LD, van Walree IC, Kolk AH, Janssen HG, Sterk PJ, Schultz MJ. Alterations in exhaled breath metabolite-mixtures in two rat models of lipopolysaccharide-induced lung injury. J Appl Physiol. 2013;115:1487-1495.
29. Arasaradnam RP, McFarlane MJ, Ryan-Fisher C, Westenbrink E, Hodges P, Thomas MG, et al. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PLoS ONE. 2014;9:e108750.
30. Bos LD, Weda H, Wang Y, Knobel HH, Nijsen TM, Vink TJ, et al. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome. Eur Respir J 2014;44(1):188-197.
31. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912-930.
32. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
33. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J. 1993;6(Suppl 16):53-83.
34. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, et al. Sputum induction. Eur Respir J Suppl. 2002;37:3s-8s.
35. Boorsma M, Lutter R, van de Pol MA, Out TA, Jansen HM, Jonkers RE. Repeatability of inflammatory parameters in induced sputum of COPD patients. Copd. 2007;4:321-329.
36. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006;78:779-787.
37. The European Commission. Commission Decision of 28 May 2014 establishing the ecological criteria for the award of the EU Ecolabel for indoor and outdoor paints and varnishes.http://data.europa.eu/eli/dec/2014/312/oj Accessed August 26, 2016
38. Box GEP, Cox DR. An Analysis of Transformations. J R Stat Soc Series B (Methodol). 1964;26:211-252.
39. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, et al. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 2007;3:95-109.
40. Basanta M, Ibrahim B, Dockry R, Douce D, Morris M, Singh D, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir Res. 2012;13:72.
41. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1–Correlation within subjects. BMJ. 1995;310:446.
42. Broadhurst D, Kell D. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics. 2006;2:171-196.
43. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Series B (Methodol). 1995;57:289-300.
44. Irizarry R, Love M. PH525x series - Biomedical Data Science - Collinearity. HarvardX Free online courses from Harvard University. http://genomicsclass.github.io/book/pages/collinearity.html. Accessed October 8, 2016
45. Yeomans KA, Golder PA. The Guttman-Kaiser Criterion as a Predictor of the Number of Common Factors. J R Stat Soc Series D (The Statistician). 1982;31:221-229.
46. Rosenthal R, Cooper H, Hedges L. Parametric measures of effect size. The handbook of research synthesis. 1994;231-244.
47. Van Vliet D, Smolinska A, Jobsis Q, Rosias PP, Muris JW, Dallinga JW, et al. Association between exhaled inflammatory markers and asthma control in children. J Breath Res. 2016;10:016014.
48. van der Schee MP, Palmay R, Cowan JO, Taylor DR. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy. 2013;43:1217-1225.
49. Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev 2016;9:Cd011440.
50. Fens N, Douma RA, Sterk PJ, Kamphuisen PW. Breathomics as a diagnostic tool for pulmonary embolism. J Thromb Haemost. 2010;8:2831-2833.
51. Lazar Z, Fens N, van der Maten J, van der Schee MP, Wagener AH, de Nijs SB, et al. Electronic nose breathprints are independent of acute changes in airway caliber in asthma. Sensors. 2010;10:9127-9138.
52. de Vries R, Brinkman P, van der Schee MP, Fens N, Dijkers E, Bootsma SK, et al. Integration of electronic nose technology with spirometry: validation of a new approach for exhaled breath analysis. J Breath Res. 2015;9:046001.
53. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr. 2007;21:553-566.
54. Moser B, Bodrogi F, Eibl G, Lechner M, Rieder J, Lirk P. Mass spectrometric profile of exhaled breath–field study by PTR-MS. Respir Physiol Neurobiol. 2005;145:295-300.
55. Bos LD, Sterk PJ, Schultz MJ. Volatile metabolites of pathogens: a systematic review. PLoS Pathog. 2013;9:e1003311.
56. Oura H, Tashiro Y, Toyofuku M, Ueda K, Kiyokawa T, Ito S, et al. Inhibition of Pseudomonas aeruginosa swarming motility by 1-naphthol and other bicyclic compounds bearing hydroxyl groups. Appl Environ Microbiol. 2015;81:2808-2818.
57. Heinis C, Rutherford T, Freund S, Winter G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat Chem Biol. 2009;5:502-507.
58. Stockdale TP, Williams CM. Pharmaceuticals that contain polycyclic hydrocarbon scaffolds. Chem Soc Rev. 2015;44:7737-7763.
59. Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy. 2009;39:193-202.